Literature DB >> 16505206

Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.

Koichi Yamamoto1, Mitsuru Ohishi, Tomohiro Katsuya, Norihisa Ito, Masashi Ikushima, Masaharu Kaibe, Yuji Tatara, Atsushi Shiota, Sumio Sugano, Satoshi Takeda, Hiromi Rakugi, Toshio Ogihara.   

Abstract

Angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase that cleaves angiotensin II to angiotensin 1-7. Recently, it was reported that mice lacking ACE2 (ACE2(-/y) mice) exhibited reduced cardiac contractility. Because mechanical pressure overload activates the cardiac renin-angiotensin system, we used ACE2(-/y) mice to analyze the role of ACE2 in the response to pressure overload. Twelve-week-old ACE2(-/y) mice and wild-type (WT) mice received transverse aortic constriction (TAC) or sham operation. Sham-operated ACE2(-/y) mice exhibited normal cardiac function and had morphologically normal hearts. In response to TAC, ACE2(-/y) mice developed cardiac hypertrophy and dilatation. Furthermore, their hearts displayed decreased cardiac contractility and increased fetal cardiac gene induction, compared with WT mice. In response to chronic pressure overload, ACE2(-/y) mice developed pulmonary congestion and increased incidence of cardiac death compared with WT mice. On a biochemical level, cardiac angiotensin II concentration and activity of mitogen-activated protein (MAP) kinases were markedly increased in ACE2(-/y) mice in response to TAC. Administration of candesartan, an AT1 subtype angiotensin receptor blocker, attenuated the hypertrophic response and suppressed the activation of MAP kinases in ACE2(-/y) mice. Activation of MAP kinases in response to angiotensin II was greater in cardiomyocytes isolated from ACE2(-/y) mice than in those isolated from WT mice. ACE2 plays an important role in dampening the hypertrophic response to pressure overload mediated by angiotensin II. Disruption of this regulatory function may accelerate cardiac hypertrophy and shorten the transition period from compensated hypertrophy to cardiac failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505206     DOI: 10.1161/01.HYP.0000205833.89478.5b

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  126 in total

Review 1.  Role of ACE2 in diastolic and systolic heart failure.

Authors:  Wang Wang; Sreedhar Bodiga; Subhash K Das; Jennifer Lo; Vaibhav Patel; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

2.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 3.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

4.  Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit.

Authors:  Sreedhar Bodiga; Jiu Chang Zhong; Wang Wang; Ratnadeep Basu; Jennifer Lo; George C Liu; Danny Guo; Steven M Holland; James W Scholey; Josef M Penninger; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Cardiovasc Res       Date:  2011-02-01       Impact factor: 10.787

Review 5.  Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look.

Authors:  Timothy L Reudelhuber; Kenneth E Bernstein; Patrick Delafontaine
Journal:  Hypertension       Date:  2007-04-23       Impact factor: 10.190

Review 6.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

7.  Apelin is a positive regulator of ACE2 in failing hearts.

Authors:  Teruki Sato; Takashi Suzuki; Hiroyuki Watanabe; Ayumi Kadowaki; Akiyoshi Fukamizu; Peter P Liu; Akinori Kimura; Hiroshi Ito; Josef M Penninger; Yumiko Imai; Keiji Kuba
Journal:  J Clin Invest       Date:  2013-11-01       Impact factor: 14.808

8.  Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.

Authors:  Yoriko Yamazato; Anderson J Ferreira; Kwon-Ho Hong; Srinivas Sriramula; Joseph Francis; Masanobu Yamazato; Lihui Yuan; Chastity N Bradford; Vinayak Shenoy; Suk P Oh; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

9.  Does ACE2 contribute to the development of hypertension?

Authors:  Mark C Chappell
Journal:  Hypertens Res       Date:  2009-12-18       Impact factor: 3.872

Review 10.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.